TABLE 1.
Demographic and clinicopathologic factors of the entire cohort
| All patients n = 352 (%) | Clinical N0 n = 151 (%) | Clinical N1-3 n = 201 (%) | |
|---|---|---|---|
| Age at diagnosis (mean ± standard deviation) | 66 ± 11 | 67 ± 12 | 66 ± 10 |
| Sex | |||
| Male | 281 (80) | 111 (73) | 170 (85) |
| Female | 71 (20) | 40 (27) | 31 (15) |
| Race | |||
| White | 322 (92) | 136 (90) | 186 (93) |
| Black | 20 (6) | 11 (7) | 9 (5) |
| Other | 10 (3) | 4 (3) | 6 (3) |
| Charlson-Deyo Score | |||
| 0 | 232 (66) | 100 (66) | 132 (66) |
| 1 | 88 (25) | 36 (24) | 52 (26) |
| 2+ | 32 (9) | 15 (10) | 17 (9) |
| Tumor size (mean ± standard deviation) | 4.5 ± 2.8 | 3.7 ± 2.1 | 5.1 ± 3 |
| Tumor differentiation | |||
| Well/moderate | 61 (21) | 31 (25) | 30 (18) |
| Poor/undifferentiated | 230 (79) | 95 (75) | 135 (82) |
| Missing | 61 | 25 | 36 |
| Clinical T stage | |||
| T1 | 58 (19) | 44 (35) | 14 (8) |
| T2 | 70 (23) | 40 (32) | 30 (16) |
| T3 | 156 (50) | 39 (31) | 117 (64) |
| T4 | 26 (8) | 4 (3) | 22 (12) |
| Missing | 42 | 24 | 18 |
| Clinical stage | |||
| 0 | 2 (0.6) | 2 (2) | 0 (0) |
| I | 55 (18) | 43 (34) | 12 (7) |
| II | 103 (34) | 78 (61) | 25 (14) |
| III | 112 (37) | 0 (0) | 112 (62) |
| IVa | 35 (11) | 4 (3) | 31 (17) |
| Missing | 45 | 24 | 21 |
| Specific tumor location | |||
| Upper thoracic esophagus | 5 (2) | 3 (4) | 1 (2) |
| Middle thoracic esophagus | 41 (20) | 19 (23) | 2 (18) |
| Lower thoracic esophagus | 132 (64) | 47 (57) | 22 (68) |
| Unknown | 13 (6) | 6 (7) | 7 (6) |
| Missing | 144 | 69 | 75 |
| Lymphovascular invasion | |||
| Present | 25 (31) | 13 (32) | 28 (70) |
| Not present | 56 (69) | 28 (68) | 12 (30) |
| Missing | 271 | 110 | 161 |
| Treatment approach | |||
| Surgery alone | 53 (15) | 43 (29) | 10 (5) |
| Chemoradiation alone | 194 (55) | 74 (49) | 120 (60) |
| Preoperative chemoradiation | 105 (30) | 34 (23) | 71 (35) |
| Follow-up, mo (median, IQR) | 41 (19-73) | 50 (18-84) | 39 (25-55) |
Abbreviation: IQR, interquartile range.